All News

2019

January

Media Release / Jan 08, 2019

Novartis investigational therapy crizanlizumab (SEG101) receives FDA Breakthrough Therapy designation for the prevention of vaso-occlusive crises in sickle cell disease

Read More
Media Release / Jan 07, 2019

Sandoz and Pear Therapeutics Announce US Launch of reSET-OTM to Help Treat Opioid Use Disorder

Read More
2018

December

Media Release / Dec 21, 2018

Novartis successfully completes acquisition of Endocyte

Read More
Media Release / Dec 21, 2018

Novartis receives European Commission (EC) approval for expanded indication for Kisqali® (ribociclib)

Read More
Media Release / Dec 20, 2018

Novartis announces offer to acquire CellforCure to expand manufacturing capacity for innovative cell and gene therapies

Read More
Media Release / Dec 20, 2018

Novartis announces new CEO of Oncology Business Unit

Read More
Media Release / Dec 19, 2018

Sandoz enters into commercialization and supply agreement for insulin biosimilars, anticipating growing demand as diabetes burden rises

Read More
Media Release / Dec 19, 2018

Alcon Announces Acquisition of Tear Film Innovations, Inc.

Read More
Media Release / Dec 13, 2018

Novartis receives European Commission approval for self-administration of Xolair® across all indications

Read More
Media Release / Dec 10, 2018

Sandoz Inc. and Pear Therapeutics Obtain FDA Clearance for reSET-O(TM) to Treat Opioid Use Disorder

Read More

Pages

Related Links

Annual Report 2017

Review the strategy and annual performance of Novartis and read letters from our Chairman and CEO.

Learn More